TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18399759

Group type: EXPERIMENTAL
Intervention: Auricular pellet acupressure
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no acupressure)
Number of subjects: 69
Study: 15750396

Group type: EXPERIMENTAL
Intervention: Case management (CM) intervention with up to five contacts over a 90-day period.
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard of care (SOC) passive referral.
Number of subjects: 273
Study: 12435467

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 0
Study: 10858333

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin followed by oral azithromycin
Number of subjects: 414

Group type: COMPARATOR
Intervention: Cefuroxime with or without erythromycin (control)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin
Number of subjects: 414

Group type: COMPARATOR
Intervention: Cefuroxime plus erythromycin (control)
Number of subjects: 414
Study: 9347429

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine (n = 8)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine (n = 9)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine (n = 8)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intravenous patient‐controlled analgesia with morphine (1.0 mg dose, 6 minute lock‐out interval)
Number of subjects: 25
Study: 8253242

Group type: EXPERIMENTAL
Intervention: Post-operative cyclopentolate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tropicamide (control)
Number of subjects: 0
Study: 3764625

Group type: EXPERIMENTAL
Intervention: Paromomycin (25-35 mg/kg daily in three divided doses for seven days)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Paromomycin
Number of subjects: 114
Study: 31534158

Group type: EXPERIMENTAL
Intervention: Visual dynamics cues (VDCs) - subjects saw the VP's affected thigh and shank
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group - subjects only saw the point-of-contact (VP ankle)
Number of subjects: 33
Study: 28758775

Group type: EXPERIMENTAL
Intervention: Dual-modality lists (6 words and 6 dots) with synchronous onsets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-modality lists (6 words and 6 dots) with alternating onsets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dual-modality lists (6 words and 6 dots) with random but asynchronous onsets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-modality lists (6 items)
Number of subjects: 0
Study: 28451931

Group type: EXPERIMENTAL
Intervention: mRYGB
Number of subjects: 45

Group type: COMPARATOR
Intervention: SG
Number of subjects: 45

Group type: COMPARATOR
Intervention: GCP
Number of subjects: 45

Group type: COMPARATOR
Intervention: Insulin treatment
Number of subjects: 45

Group type: COMPARATOR
Intervention: Increase in GLP-1 AUC from baseline to month 1
Number of subjects: 45
Study: 26178720

Group type: EXPERIMENTAL
Intervention: CHEESE diet
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: MEAT diet
Number of subjects: 14

Group type: COMPARATOR
Intervention: CARB diet
Number of subjects: 14
Study: 24007947

Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 257

Group type: COMPARATOR
Intervention: No epidural analgesia
Number of subjects: 257
Study: 21383849

Group type: EXPERIMENTAL
Intervention: Manipulation of post-saccadic visual information with varying target presentation durations (15, 50, 100, or 800 ms) during adaptation sessions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual mask following the displaced target during voluntary saccades adaptation task.
Number of subjects: 0
Study: 17377932

Group type: EXPERIMENTAL
Intervention: Weibull survival model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Exponential model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-parametric method (Kaplan-Meier estimate)
Number of subjects: 0
Study: 16990080

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Valdecoxib 40 mg
Number of subjects: 251
Study: 12700612

Group type: EXPERIMENTAL
Intervention: Soy-based meal replacement (240 g/day, 1200 kcal/day)
Number of subjects: 100
Study: 11092464

Group type: EXPERIMENTAL
Intervention: Pamidronate + chemotherapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 62
Study: 9072217

Group type: EXPERIMENTAL
Intervention: TIMOPTOL 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: VISTAGAN 0.5%
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: BETOPTIC 0.5%
Number of subjects: 60
Study: 1606097

Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine subcutaneously (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 150 micrograms clonidine mixed with local anesthetic (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% mepivacaine plus 1:200,000 epinephrine (Group A)
Number of subjects: 30
Study: 30958851

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 32
Study: 27632878

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV) - 30 Hz, amplitude 4 mm, 2 min
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control Group (CG) - WBV machine turned off
Number of subjects: 13
Study: 26115796

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg
Number of subjects: 540

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg
Number of subjects: 540

Group type: COMPARATOR
Intervention: Chemotherapy (investigator-choice)
Number of subjects: 540
Study: 23254550

Group type: EXPERIMENTAL
Intervention: High volume group (HVG, n = 7, 1,560 jumps)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Moderate volume hard surface group (MVGHS, n = 8, 780 jumps)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Moderate volume group (MVG, n = 9, 780 jumps)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CG, n = 5)
Number of subjects: 29
Study: 21063132

Group type: EXPERIMENTAL
Intervention: Asymmetry neurofeedback training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 0
Study: 20304984

Group type: EXPERIMENTAL
Intervention: Burn patients (n=9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control patients (n=6)
Number of subjects: 15
Study: 17990229

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 53

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 53
Study: 15892857

Group type: EXPERIMENTAL
Intervention: BB-10153 (0.08, 0.2, 0.6, 1.2, 1.8, 2.4, 3.6, 4.8 mg kg(‐1))
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 12473883

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional treatment (fistulotomy)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 42
Study: 9744187

Group type: EXPERIMENTAL
Intervention: Postcard reminder mailed in April
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 325
Study: 7657042

Group type: EXPERIMENTAL
Intervention: OME + AMX (high-dose omeprazole 2 x 40 mg and amoxicillin 2 x 1,000 mg for 10 days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: OME (high-dose omeprazole 2 x 40 mg)
Number of subjects: 52
Study: 2760248

Group type: EXPERIMENTAL
Intervention: 0.1% chlorhexidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (basic oral hygiene programme without chlorhexidine)
Number of subjects: 0
Study: 945952

Group type: EXPERIMENTAL
Intervention: Bupivacaine HCl
Number of subjects: 99

Group type: COMPARATOR
Intervention: Tetracaine HCl
Number of subjects: 99
Study: 31279870

Group type: EXPERIMENTAL
Intervention: Ustekinumab (90 mg every 8 weeks)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Ustekinumab (every 12 weeks)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Ustekinumab (every 8 weeks)
Number of subjects: 251
Study: 28087644

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg intravenously every 2 weeks)
Number of subjects: 120
Study: 27941110

Group type: EXPERIMENTAL
Intervention: Trained mothers (MUMs) providing rectal artesunate treatment
Number of subjects: 54013

Group type: COMPARATOR
Intervention: Community-based health workers (CHWs) providing rectal artesunate treatment
Number of subjects: 54013

Group type: COMPARATOR
Intervention: Trained traditional healers (THs) providing rectal artesunate treatment
Number of subjects: 54013

Group type: COMPARATOR
Intervention: Trained community-chosen personnel (COMs) providing rectal artesunate treatment
Number of subjects: 54013
Study: 24214029

Group type: EXPERIMENTAL
Intervention: Minimal extracorporeal circulation (MECC)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC) with dexamethasone
Number of subjects: 87
Study: 22089326

Group type: EXPERIMENTAL
Intervention: 1 mg/kg of tramadol
Number of subjects: 110

Group type: COMPARATOR
Intervention: 1 μg/kg of fentanyl
Number of subjects: 110
Study: 19755887

Group type: EXPERIMENTAL
Intervention: Discharge facilitator (DF) providing verbal reinforcement of written discharge instructions in the parent's language of choice.
Number of subjects: 227

Group type: COMPARATOR
Intervention: Standard discharge group receiving written discharge instructions and standard ED discharge protocols.
Number of subjects: 227
Study: 17550919

Group type: EXPERIMENTAL
Intervention: Artificial turf
Number of subjects: 2020

Group type: COMPARATOR
Intervention: Natural grass
Number of subjects: 2020

Group type: EXPERIMENTAL
Intervention: Overall (both surfaces)
Number of subjects: 2020
Study: 14728708

Group type: EXPERIMENTAL
Intervention: Light exposure (300 lx) for 30 min between 00.30 and 01.00 h
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo for 30 min between 00.30 and 01.00 h
Number of subjects: 24
Study: 11520775

Group type: EXPERIMENTAL
Intervention: DAT (daunorubicin, cytarabine, and thioguanine)
Number of subjects: 1314

Group type: COMPARATOR
Intervention: ADE (daunorubicin, cytarabine, and etoposide)
Number of subjects: 1314

Group type: COMPARATOR
Intervention: MAC (mitoxantrone‐cytarabine)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: Granulocyte colony‐stimulating factor (G‐CSF)
Number of subjects: 1314

Group type: COMPARATOR
Intervention: 3-course treatment (DAT 2 + 7)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: 6-course treatment (subsequent COAP, DAT 2 + 5, and COAP)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: 12-month maintenance treatment with low-dose interferon
Number of subjects: 1314
Study: 10193281

Group type: EXPERIMENTAL
Intervention: Epidural analgesia with ropivacaine 2.5 mg ml‐1
Number of subjects: 403

Group type: COMPARATOR
Intervention: Epidural analgesia with bupivacaine 2.5 mg ml‐1
Number of subjects: 403
Study: 7850820

Group type: EXPERIMENTAL
Intervention: Enoximone (1 mg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Digoxin (0.01 mg/kg)
Number of subjects: 8
Study: 3182329

Group type: EXPERIMENTAL
Intervention: 5-FU administered at a dose of 300 mg/m2 days 1-5 and 28-32 (Group A)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 5-FU administered at a dose of 300 mg/m2 days 1-3 and 28-31 (Group B)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Whole abdominal radiation (3000 rads) with a 1600 rad boost to the tumor bed for B2 or C2 patients
Number of subjects: 38
Study: 31573637

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin C infusion (50 mg/kg in dextrose 5% in water, n=84)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (dextrose 5% in water only, n=83)
Number of subjects: 167
Study: 27410907

Group type: EXPERIMENTAL
Intervention: Atomoxetine (1.0‐1.4 mg/kg/day)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 26369655

Group type: EXPERIMENTAL
Intervention: Rebamipide 0.1 g three times per day for 26 weeks
Number of subjects: 178
Study: 23039158

Group type: EXPERIMENTAL
Intervention: AH Plus sealer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MTA Flow sealer
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both groups (AH Plus and MTA Flow)
Number of subjects: 16
Study: 22413384

Group type: EXPERIMENTAL
Intervention: Multiple family group service delivery model
Number of subjects: 2
Study: 19299670

Group type: EXPERIMENTAL
Intervention: 2-year multicomponent, school-based intervention including behavioral classroom curricula, school posters, parental involvement, and peer-led activism
Number of subjects: 14063

Group type: EXPERIMENTAL
Intervention: 2-year multicomponent, school-based intervention
Number of subjects: 14063

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 14063
Study: 18154993

Group type: EXPERIMENTAL
Intervention: Use of high-risk conduits (diameter <3mm or nonsingle segment GSV)
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: High-risk conduits
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Vein diameter <3.5 mm
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Non-great saphenous vein (GSV) type
Number of subjects: 1404

Group type: EXPERIMENTAL
Intervention: Graft lengths >50 cm
Number of subjects: 1404

Group type: COMPARATOR
Intervention: Technical variables
Number of subjects: 1404
Study: 16130875

Group type: EXPERIMENTAL
Intervention: Lubrication‐free handpiece
Number of subjects: 180

Group type: COMPARATOR
Intervention: Handpiece requiring routine lubrication (automated application)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Handpiece requiring routine lubrication (manual application)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Total‐etch, two‐step bonding agent
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Self‐etch, two‐step bonding agent
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Self‐etch, one‐step bonding agent
Number of subjects: 180
Study: 12103366

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (NSAID, Naproxen sodium)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: NSAID plus inactive TENS
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 9918478

Group type: EXPERIMENTAL
Intervention: Orlistat, 120 mg 3 times a day
Number of subjects: 892

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 892

Group type: EXPERIMENTAL
Intervention: Orlistat, 60 mg
Number of subjects: 892
Study: 8787955

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (DF) 15 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine (DF)
Number of subjects: 24
Study: 2286486

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonexercise group (Control)
Number of subjects: 36
Study: 19803010

Group type: EXPERIMENTAL
Intervention: Ceftazidime (1 to 6 g daily im or iv)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftazidime (1 g im)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftazidime (1 and 2 g im 12‐hourly)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftazidime (0.5 g 12‐hourly)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 45
Study: 30788757

Group type: EXPERIMENTAL
Intervention: CCTA (n=200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: MPI (n=200)
Number of subjects: 400
Study: 30803411

Group type: EXPERIMENTAL
Intervention: Long-term Methimazole (MMI)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Radioiodine (RAI)
Number of subjects: 130
Study: 29151416

Group type: EXPERIMENTAL
Intervention: Short-term deep sedation (midazolam 0.1-0.2 mg/kg, RASS score -4 to -3, duration no more than 12 hours)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Short-term deep sedation
Number of subjects: 106
Study: 26478943

Group type: EXPERIMENTAL
Intervention: IN-BMI (injunctive norms brief motivational intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined-BMI (combined injunctive and descriptive norms brief motivational intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DN-BMI (descriptive norms brief motivational intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 0
Study: 23621600

Group type: EXPERIMENTAL
Intervention: Microsurgical clip occlusion
Number of subjects: 471

Group type: COMPARATOR
Intervention: Endovascular coil embolization
Number of subjects: 471
Study: 20661607

Group type: EXPERIMENTAL
Intervention: Gradia Core/Ellipson tip and post
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gradia Core/MtwoPF and DT Light-Post
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Corecem Automix/Ellipson tip and post
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Corecem Automix/MtwoPF and DT Light-Post
Number of subjects: 20
Study: 19028780

Group type: EXPERIMENTAL
Intervention: Percutaneous intervention (PCI), n = 1101
Number of subjects: 2201

Group type: COMPARATOR
Intervention: Medical therapy (MED), n = 1100
Number of subjects: 2201
Study: 16880785

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice daily (b.i.d.)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Sorafenib (randomised group)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (randomised group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Overall (all patients)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Randomised patients with stable disease
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 37
Study: 15701188

Group type: EXPERIMENTAL
Intervention: Humidified, heated gas
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dry, heated gas
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard dry, cold gas (control group)
Number of subjects: 90
Study: 11340825

Group type: EXPERIMENTAL
Intervention: Weekly teaching group (1 hour/week for 10 weeks)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intensive teaching group (2 hours daily for 5 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 15562667

Group type: EXPERIMENTAL
Intervention: Cost assessments in the management of variceal hemorrhage
Number of subjects: 0
Study: 7957152

Group type: EXPERIMENTAL
Intervention: BCAA infusion (260 mg x kg‐1 x h‐1 for 70 min)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6
Study: 3357367

Group type: EXPERIMENTAL
Intervention: Passive upright tilt (1 minute at 15 degrees, 2 minutes at 45 degrees, 7 minutes at 85 degrees)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo administration before passive upright tilt
Number of subjects: 35
Study: 29988969

Group type: EXPERIMENTAL
Intervention: internet‐based cognitive‐behavioural therapy (iCBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: attention control
Number of subjects: 70
Study: 28161309

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OT) administration
Number of subjects: 79
Study: 26032206

Group type: EXPERIMENTAL
Intervention: vitD3 supplementation (7,000 IU/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 56
Study: 23085729

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (ONS)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: ONS indication
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group (patients without ONS)
Number of subjects: 470
Study: 21558574

Group type: EXPERIMENTAL
Intervention: GliSODin extract (500 mg, 2 capsules once daily for 6 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 19365716

Group type: EXPERIMENTAL
Intervention: 30-week social competence and social skills group intervention program
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 18
Study: 17011760

Group type: EXPERIMENTAL
Intervention: Alprostadil (prostaglandin E(1) analogue) administered during operation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group without alprostadil
Number of subjects: 42
Study: 15327935

Group type: EXPERIMENTAL
Intervention: Unimodal tactile or visual stimuli
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cross-modal (tactile and visual) stimuli
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 16
Study: 11550161

Group type: EXPERIMENTAL
Intervention: 0.15% benzydamine oral rinse, 15 mL for 2 minutes, 4-8 times daily before and during RT, and for 2 weeks after completion of RT.
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: 0.15% benzydamine oral rinse
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Accelerated RT doses (> or = 220 cGy/day)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Benzydamine and placebo
Number of subjects: 145
Study: 9248981

Group type: EXPERIMENTAL
Intervention: Cytokine gene expression detection using RT-PCR in severely infected patients
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cytokine gene expression detection using RT-PCR in healthy volunteers
Number of subjects: 6
Study: 8271169

Group type: EXPERIMENTAL
Intervention: Carbachol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 60

Group type: COMPARATOR
Intervention: BSS (Balanced Salt Solution)
Number of subjects: 60
Study: 3135572

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-gamma (50 micrograms daily for 20 days, then 50 micrograms every second day up to day 28, subcutaneous injection)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 30244430

Group type: EXPERIMENTAL
Intervention: Modular common elements approach to evidence-based practices (EBPs) training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-modular evidence-based practices (EBPs) training
Number of subjects: 80
Study: 28774663

Group type: EXPERIMENTAL
Intervention: Fast-track insertion (≤3 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Delayed insertion (2-4 weeks)
Number of subjects: 108